State and School Employees' Health Insurance Plan - Fetroja (cefiderocol sulfate tosylate)
Summary
Fetroja (cefiderocol sulfate tosylate) may be considered medically necessary for individuals older than 18 who have complicated urinary tract infection, including pyelonephritis, caused by listed susceptible Gram-negative organisms, or hospital-acquired or ventilator-associated bacterial pneumonia caused by listed susceptible Gram-negative organisms. Coverage requires culture and sensitivity testing that identifies the pathogen and demonstrates susceptibility to the requested medication, with documentation, and requires that the individual has limited or no alternative treatment options and no FDA-labeled contraindication to the requested agent. Length of approval is up to 14 days. The 12/02/2025 update added that the use of samples by an individual will not be considered current or stable therapy.
Get alerts when payers change rules like this one
We check Blue Cross & Blue Shield of Mississippi and other payers every day and email you when a change matches your specialty and state.